A New Vaccine Against Depression? | MYND Life Sciences

By |

Watch

Midas Letter

The Digital Businesss Channel for Cannabis, Crypto and Technology Stocks.

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

Midas Letter
Midas Letter
A New Vaccine Against Depression? | MYND Life Sciences
/

MYND Life Sciences (CNSX:MYND) is a company exploring anti-inflammatory benefits of psilocybin and other psychedelic compounds as they apply to depression and other central nervous system (CNS) disorders.

There have been a lot of breakthroughs over the last decade defining what causes depression. Historically, depression has been diagnosed based on a checklist of symptoms system. It is now theory that depression can be looked at as neuro-inflammation. MYND has been concentrating on how psychedelics scientifically affect the brain and can be used as an anti-inflammatory for the last decade. The research already carried out suggests that psilocybin and psychedelic analogs can be used to treat this inflammation and ultimately depression as a whole.

“Just signed a licensing agreement for, get this? A vaccine against depression, against the inflammatory process. A little bit Star Trek-ish, but on the other hand when you have a physical cause, that’s where we are in health care in 2021.” – MYND Life Sciences CEO Dr. Lyle Oberg

MYND is currently driving toward the initiation of up to six clinical trials on the efficacy of psilocybin and psilocybin analogs by the end of this year. These clinical trials are looking into sepsis, cytokine storm, depression, and biomarkers. MYND expects to be revenue-generating and have a drug available to the public by the middle of next year.

Watch the full interview to learn about MYND’s 4 patents, its Section J exemptions studying 38 different psychedelic analogs, its work with the FDA/Health Canada, and its projected pathway to revenue.

Transcript

00:00 – MYND Life Sciences CEO Dr Lyle Oberg

00:37 – MYND Life Sciences overview

02:29 – Psychedelic research

04:04 – Clinical trials

05:49 – Timeline until treatments are available to patients

06:34 – Pathway to revenue

08:25 – Regulatory environment changes

10:01 – Publishing research

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.